The increase in responsiveness to cancer immunotherapy with obesity in many cancer types suggests that obesity-associated immunosuppressive factors can be overcome with the removal of inhibitory signals like PD-(L)1 signaling. This evidence concerns the gene CD274 and obesity due to melanocortin 4 receptor deficiency.